Remove tag japan
article thumbnail

PharmaShots Weekly Snapshots (May 29 - June 02, 2023)

PharmaShots

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

FDA 40
article thumbnail

PharmaShots Weekly Snapshots (June 19 – 23, 2023)

PharmaShots

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (June 12 – 16, 2023)

PharmaShots

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40
article thumbnail

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

PharmaShots

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40
article thumbnail

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

pharmaphorum

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

FDA 108
article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

Kaneka Corporation (Japan). Tag Copenhagen A/S (Denmark). CSBIO (US). Danaher Corporation (US). Eton Bioscience, Inc. (US). Eurofins Scientific (Germany). Ionis Pharmaceuticals, Inc. (US). LGC Limited (UK). Thermo Fisher Scientific, Inc. (US). Twist Bioscience Corporation (US). Maravai Life Sciences (US). Merck KGaA (Germany).

article thumbnail

Anti-Counterfeiting Technologies in Healthcare

Roots Analysis

Examples of such technologies include DNA Taggants (a unique DNA tag used in the product / packaging that can be scanned using a designated instrument / equipment), invisible printing technologies, digital watermark technologies and hidden markers / print technologies.